Medivir AB – Initiating as an Outperform - Next in HCV- A Once Daily Protease Inhibitor Option

https://marketpublishers.com/r/MCC6E96BEFBEN.html

Date: June 2011
Pages: 6
Price: US$ 140.00 (Single User License)
ID: MCC6E96BEFBEN

Abstracts

We initiate our coverage on Medivir AB (MVIR) with an Outperform rating, as TMC435 (Protease Inhibitor, PhII/III, partnered with Tibotec/JNJ) could offer compelling advantages over recently launched PIs Incivek (Vertex/JNJ) and Victrelis (Merck). MVIR has a diversified Portfolio consists of both marketed and mature programs targeting viral diseases. TMC435 offers Dosing Advantage, once/daily pill vs. Incivek 2pills/3d and Merck's Victrelis 4pills/3d besides…. For more detail, please read our report released on 24th June, 2011 on MVIR titled "Next in HCV- A Once Daily Protease Inhibitor Option".

Contents

COMPANIES MENTIONED

Medivir AB, MVIR

I would like to order

Product name: Medivir AB – Initiating as an Outperform - Next in HCV- A Once Daily Protease Inhibitor Option

Product link: https://marketpublishers.com/r/MCC6E96BEFBEN.html

Price: US$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MCC6E96BEFBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970